Business Context and Reporting Period
Company: Impact BioMedical, Inc. (Ticker: IBIO on NYSE American)
Filing Type: Form 10-Q (Unaudited)
Period: Quarter and nine months ended September 30, 2024
Business Overview: The Company discovers and patents technologies for human healthcare and wellness, focusing on oncology, inflammatory disorders, and neurology. Key assets include the Linebacker™ platform, Laetose™ (sugar substitute), Functional Fragrance Formulation (3F), and Equivir™. The Company operates primarily through licensing and strategic partnerships.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2024 | Nine Months Ended Sept 30, 2024 | As of Sept 30, 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Income (Loss) | $4,241,000 | $2,363,000 | N/A |
| Operating Loss | $(1,127,000) | $(2,522,000) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $2,668,000 |
| Total Assets | N/A | N/A | $46,695,000 |
| Total Liabilities | N/A | N/A | $12,344,000 |
| Stockholders' Equity | N/A | N/A | $34,351,000 |
| Related Party Debt (Net) | N/A | N/A | $8,006,000 |
Note: Net income is driven primarily by a non-cash gain on the change in fair value of an embedded derivative, not operational revenue.
Material Changes vs. Prior Period
- Profitability Shift: The Company reported a Net Income of $4.24 million for Q3 2024, compared to a Net Loss of $1.18 million in Q3 2023. This reversal is almost entirely attributable to a $5.67 million non-cash gain from the change in fair value of an embedded derivative in a related-party note. Operating losses persisted at $1.13 million.
- Liquidity Improvement: Cash and cash equivalents increased from $1,000 at December 31, 2023, to $2.67 million at September 30, 2024. This was driven by a September 2024 Initial Public Offering (IPO) raising $3.73 million net of costs and borrowings from a related party.
- Expense Fluctuations:
- Sales & Marketing: Increased 2,612% in Q3 2024 ($461k vs $17k) due to IPO-related marketing and trade shows.
- R&D: Decreased 77% in Q3 2024 ($82k vs $357k) following the termination of a research contract with GRDG in late 2023.
- Professional Fees: Decreased 62% in Q3 2024 ($122k vs $317k) as IPO-related legal costs were incurred in prior periods.
- Debt Restructuring: A related-party revolving note was amended in July 2024 to allow repayment via equity and adjust interest rates, resulting in the recognition of the embedded derivative gain.
Outlook, Risks, and Unusual Items
- Going Concern: The filing states that historical operating losses and negative cash flows raise substantial doubt about the Company's ability to continue as a going concern. Management plans to address this through the monetization of intellectual property and cost controls.
- Unusual Item (Derivative Gain): The $5.67 million gain on the change in fair value of an embedded derivative is a non-cash item that significantly distorts net income. Investors should focus on the operating loss of $1.13 million for the quarter.
- Capital Markets: The Company completed its IPO on September 16, 2024, listing on the NYSE American. 1.5 million shares were sold, with 9.99 million shares remaining restricted for 180 days.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2024, citing material weaknesses identified in the prior year's 10-K that remain unremediated.
- Risks: The Company has not generated significant revenue from operations. Future success depends on licensing agreements and commercialization of technologies which are still in development.
Investor Verification Checklist
- Revenue Reality: Verify that the reported Net Income is non-operational and driven by accounting adjustments (derivative valuation) rather than product sales.
- Cash Burn Rate: Assess the sustainability of the $2.67 million cash balance against the $2.52 million operating loss for the nine-month period.
- Related Party Exposure: Review the terms of the $8 million related-party debt and the embedded derivative valuation methodology, as this significantly impacts the balance sheet and income statement.
- Internal Controls: Investigate the status of remediation for the material weaknesses in internal controls over financial reporting.
- Commercialization Progress: Confirm the status of licensing deals with partners like ProPhase Laboratories and Chemia Corporation to determine if future revenue streams are viable.